AAAAAA
Results:
1-20
|
Results: 20
Authors:
Wolfers, J
Lozier, A
Raposo, G
Regnault, A
Thery, C
Masurier, C
Flament, C
Pouzieux, S
Faure, F
Tursz, T
Angevin, E
Amigorena, S
Zitvogel, L
Citation: J. Wolfers et al., Tumor-derived exosomes are a source of shared tumor rejection antigens forCTL cross-priming, NAT MED, 7(3), 2001, pp. 297-303
Authors:
Ikarashi, Y
Mikami, R
Bendelac, A
Terme, M
Chaput, N
Terada, M
Tursz, T
Angevin, E
Lemonnier, FA
Wakasugi, H
Zitovogel, L
Citation: Y. Ikarashi et al., Dendritic cell maturation overrules H-2D-mediated natural killer T (NKT) cell inhibition: Critical role for B7 in CD1d-dependent NKT cell interferon gamma production, J EXP MED, 194(8), 2001, pp. 1179-1186
Authors:
Molinier-Frenkel, V
Le Boulaire, C
Le Gal, FA
Gahery-Segard, H
Tursz, T
Guillet, JG
Farace, F
Citation: V. Molinier-frenkel et al., Longitudinal follow-up of cellular and humoral immunity induced by recombinant adenovirus-mediated gene therapy in cancer patients, HUM GENE TH, 11(13), 2000, pp. 1911-1920
Authors:
Ahomadegbe, JC
Tourpin, S
Kaghad, M
Zelek, L
Vayssade, M
Mathieu, MC
Rochard, F
Spielmann, M
Tursz, T
Caput, D
Riou, G
Benard, J
Citation: Jc. Ahomadegbe et al., Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: Prevalence of alterations in inflammatory breast cancers, ONCOGENE, 19(47), 2000, pp. 5413-5418
Authors:
Zitvogel, L
Angevin, E
Tursz, T
Citation: L. Zitvogel et al., Dendritic cell-based immunotherapy of cancer, ANN ONCOL, 11, 2000, pp. 199-205
Authors:
Escudier, B
Andre, F
Baldeyrou, P
Le Cesne, A
Le Chevalier, T
Tursz, T
Citation: B. Escudier et al., Gene therapy and lung cancer: today and tomorrow., REV MAL RES, 17(1), 2000, pp. 363-370
Authors:
Le Cesne, A
Judson, I
Crowther, D
Rodenhuis, S
Keizer, HJ
Van Hoesel, Q
Blay, JY
Frisch, J
Van Glabbeke, M
Hermans, C
Van Oosterom, A
Tursz, T
Verweij, J
Citation: A. Le Cesne et al., Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group, J CL ONCOL, 18(14), 2000, pp. 2676-2684
Authors:
Molinier-Frenkel, V
Gawery-Segard, H
Mentali, M
Le Boulaire, C
Ribault, S
Boulanger, P
Tursz, T
Guillet, JG
Farace, F
Citation: V. Molinier-frenkel et al., Immune response to recombinant adenovirus in humans: Capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes, J VIROLOGY, 74(16), 2000, pp. 7678-7682
Authors:
Badie, C
Bourhis, J
Sobczak-Thepot, J
Haddada, H
Chiron, M
Janicot, M
Janot, F
Tursz, T
Vassal, G
Citation: C. Badie et al., p53-dependent G2 arrest associated with a decrease in cyclins A2 and B1 levels in a human carcinoma cell line, BR J CANC, 82(3), 2000, pp. 642-650
Authors:
Le Cesne, A
Vassal, G
Farace, F
Spielmann, M
Le Chevalier, T
Angevin, E
Valteau-Couanet, D
Fizazi, K
Cojean, I
Llombard, A
Tursz, T
Escudier, B
Citation: A. Le Cesne et al., Combination interleukin-2 and doxorubicin in advanced adult solid tumors: Circumvention of doxorubicin resistance in soft-tissue sarcoma?, J IMMUNOTH, 22(3), 1999, pp. 268-277
Authors:
Fernandez, NC
Lozier, A
Flament, C
Ricciardi-Castagnoli, P
Bellet, D
Suter, M
Perricaudet, M
Tursz, T
Maraskovsky, E
Zitvogel, L
Citation: Nc. Fernandez et al., Dendritic cells directly trigger NK cell functions: Cross-talk relevant ininnate anti-tumor immune responses in vivo, NAT MED, 5(4), 1999, pp. 405-411
Authors:
Lapierre, V
Auperin, A
Benhamou, E
Tursz, T
Citation: V. Lapierre et al., A specific approval procedure for prescribing albumin: Impact on consumption in a cancer treatment institution, ANN ONCOL, 10(2), 1999, pp. 244-245
Authors:
Van Glabbeke, M
van Oosterom, AT
Oosterhuis, JW
Mouridsen, H
Crowther, D
Somers, R
Verweij, J
Santoro, A
Buesa, J
Tursz, T
Citation: M. Van Glabbeke et al., Prognostic factors for the outcome of chemotherapy in advanced soft tissuesarcoma: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens - A European Organization for Research and Treatmentof Cancer Soft Tissue and Bone Sarcoma Group Study, J CL ONCOL, 17(1), 1999, pp. 150-157
Authors:
Merimsky, O
Terrier, P
Stanca, A
Le Chevalier, T
Spielmann, M
Tursz, T
Le Cesne, A
Citation: O. Merimsky et al., Liver metastases from extremity soft tissue sarcoma, AM J CL ONC, 22(1), 1999, pp. 70-72
Authors:
Ardila-Osorio, H
Clausse, B
Mishal, Z
Wiels, J
Tursz, T
Busson, P
Citation: H. Ardila-osorio et al., Evidence of LMP1-TRAF3 interactions in glycosphingolipid-rich complexes oflymphoblastoid and nasopharyngeal carcinoma cells, INT J CANC, 81(4), 1999, pp. 645-649
Authors:
Sbih-Lammali, F
Clausse, B
Ardila-Osorio, H
Guerry, R
Talbot, M
Havouis, S
Ferradini, L
Bosq, J
Tursz, T
Busson, P
Citation: F. Sbih-lammali et al., Control of apoptosis in Epstein Barr virus-positive nasopharyngeal carcinoma cells: Opposite effects of CD95 and CD40 stimulation, CANCER RES, 59(4), 1999, pp. 924-930
Authors:
Meunier, F
Torfs, K
Hildebrand, J
Piccart, M
Otten, J
Wils, J
Hall, R
Pecorelli, S
Lefebvre, J
Willemze, A
De Pauw, B
Noordijk, E
Eggermont, A
Tursz, T
Chevallier, B
Tirelli, U
Monfardini, S
Giaccone, G
Bartelink, H
Kaasa, S
Citation: F. Meunier et al., Cost evaluation of treatment modalities in cancer patients, BIOM HLTH R, 24, 1998, pp. 362-369
Authors:
Fizazi, K
Dohollou, N
Blay, JY
Guerin, S
Le Cesne, A
Andre, F
Pouillart, P
Tursz, T
Bui, NB
Citation: K. Fizazi et al., Ewing's family of tumors in adults: Multivariate analysis of survival and long-term results of multimodality therapy in 182 patients, J CL ONCOL, 16(12), 1998, pp. 3736-3743
Authors:
Llombart-Cussac, A
Pivot, X
Contesso, G
Rhor-Alvarado, A
Delord, JP
Spielmann, M
Tursz, T
Le Cesne, A
Citation: A. Llombart-cussac et al., Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience, BR J CANC, 78(12), 1998, pp. 1624-1628
Authors:
Nielsen, OS
Dombernowsky, P
Mouridsen, H
Crowther, D
Verweij, J
Buesa, J
Steward, W
Daugaard, S
van Glabbeke, M
Kirkpatrick, A
Tursz, T
Citation: Os. Nielsen et al., High-dose epirubicin is not an alternative to standard-dose doxorubicin inthe treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group, BR J CANC, 78(12), 1998, pp. 1634-1639
Risultati:
1-20
|